Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18559761rdf:typepubmed:Citationlld:pubmed
pubmed-article:18559761lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:18559761lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:18559761lifeskim:mentionsumls-concept:C0854850lld:lifeskim
pubmed-article:18559761lifeskim:mentionsumls-concept:C0039082lld:lifeskim
pubmed-article:18559761lifeskim:mentionsumls-concept:C1522690lld:lifeskim
pubmed-article:18559761lifeskim:mentionsumls-concept:C1096776lld:lifeskim
pubmed-article:18559761lifeskim:mentionsumls-concept:C0023981lld:lifeskim
pubmed-article:18559761lifeskim:mentionsumls-concept:C0205179lld:lifeskim
pubmed-article:18559761pubmed:issue6lld:pubmed
pubmed-article:18559761pubmed:dateCreated2008-6-18lld:pubmed
pubmed-article:18559761pubmed:abstractTextTo assess the rate of objective response to pegylated liposomal doxorubicin hydrochloride (Caelyx) in patients with advanced or refractory cutaneous T-cell lymphoma (CTCL).lld:pubmed
pubmed-article:18559761pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18559761pubmed:languageenglld:pubmed
pubmed-article:18559761pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18559761pubmed:citationSubsetAIMlld:pubmed
pubmed-article:18559761pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18559761pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18559761pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18559761pubmed:statusMEDLINElld:pubmed
pubmed-article:18559761pubmed:monthJunlld:pubmed
pubmed-article:18559761pubmed:issn1538-3652lld:pubmed
pubmed-article:18559761pubmed:authorpubmed-author:ClaudyAlainAlld:pubmed
pubmed-article:18559761pubmed:authorpubmed-author:JolyPascalPlld:pubmed
pubmed-article:18559761pubmed:authorpubmed-author:DrenoBrigitte...lld:pubmed
pubmed-article:18559761pubmed:authorpubmed-author:BedaneChristo...lld:pubmed
pubmed-article:18559761pubmed:authorpubmed-author:VabresPierrePlld:pubmed
pubmed-article:18559761pubmed:authorpubmed-author:DereureOlivie...lld:pubmed
pubmed-article:18559761pubmed:authorpubmed-author:MartinLudovic...lld:pubmed
pubmed-article:18559761pubmed:authorpubmed-author:GrangeFlorent...lld:pubmed
pubmed-article:18559761pubmed:authorpubmed-author:Beylot-BarryM...lld:pubmed
pubmed-article:18559761pubmed:authorpubmed-author:KhammariAmirAlld:pubmed
pubmed-article:18559761pubmed:authorpubmed-author:NguyenJean-Mi...lld:pubmed
pubmed-article:18559761pubmed:authorpubmed-author:DelaunayMiche...lld:pubmed
pubmed-article:18559761pubmed:authorpubmed-author:D'incanMichel...lld:pubmed
pubmed-article:18559761pubmed:authorpubmed-author:QuereuxGaëlle...lld:pubmed
pubmed-article:18559761pubmed:authorpubmed-author:MarquesSoniaSlld:pubmed
pubmed-article:18559761pubmed:authorpubmed-author:PuzenatElisab...lld:pubmed
pubmed-article:18559761pubmed:authorpubmed-author:CelerierPhili...lld:pubmed
pubmed-article:18559761pubmed:authorpubmed-author:SasolasBrunoBlld:pubmed
pubmed-article:18559761pubmed:issnTypeElectroniclld:pubmed
pubmed-article:18559761pubmed:volume144lld:pubmed
pubmed-article:18559761pubmed:ownerNLMlld:pubmed
pubmed-article:18559761pubmed:authorsCompleteYlld:pubmed
pubmed-article:18559761pubmed:pagination727-33lld:pubmed
pubmed-article:18559761pubmed:meshHeadingpubmed-meshheading:18559761...lld:pubmed
pubmed-article:18559761pubmed:meshHeadingpubmed-meshheading:18559761...lld:pubmed
pubmed-article:18559761pubmed:meshHeadingpubmed-meshheading:18559761...lld:pubmed
pubmed-article:18559761pubmed:meshHeadingpubmed-meshheading:18559761...lld:pubmed
pubmed-article:18559761pubmed:meshHeadingpubmed-meshheading:18559761...lld:pubmed
pubmed-article:18559761pubmed:meshHeadingpubmed-meshheading:18559761...lld:pubmed
pubmed-article:18559761pubmed:meshHeadingpubmed-meshheading:18559761...lld:pubmed
pubmed-article:18559761pubmed:meshHeadingpubmed-meshheading:18559761...lld:pubmed
pubmed-article:18559761pubmed:meshHeadingpubmed-meshheading:18559761...lld:pubmed
pubmed-article:18559761pubmed:meshHeadingpubmed-meshheading:18559761...lld:pubmed
pubmed-article:18559761pubmed:meshHeadingpubmed-meshheading:18559761...lld:pubmed
pubmed-article:18559761pubmed:meshHeadingpubmed-meshheading:18559761...lld:pubmed
pubmed-article:18559761pubmed:meshHeadingpubmed-meshheading:18559761...lld:pubmed
pubmed-article:18559761pubmed:meshHeadingpubmed-meshheading:18559761...lld:pubmed
pubmed-article:18559761pubmed:meshHeadingpubmed-meshheading:18559761...lld:pubmed
pubmed-article:18559761pubmed:meshHeadingpubmed-meshheading:18559761...lld:pubmed
pubmed-article:18559761pubmed:meshHeadingpubmed-meshheading:18559761...lld:pubmed
pubmed-article:18559761pubmed:year2008lld:pubmed
pubmed-article:18559761pubmed:articleTitleProspective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sézary syndrome.lld:pubmed
pubmed-article:18559761pubmed:affiliationDepartments of Dermatology, Centre Hospitalier Universitaire, Nantes, France.lld:pubmed
pubmed-article:18559761pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18559761pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:18559761pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:18559761pubmed:publicationTypeMulticenter Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18559761lld:pubmed